AbbVie Inc

ABBV remains in a long-term uptrend, evidenced by a rising 200-day SMA, but its break below the 9/20 EMAs and flattening 50-day SMA signals medium-term weakness. The medium-term bias stays bullish under the current Stage 2 advancing context, yet short-term conditions are unfavorable for immediate entry. Growth at Reasonable Price strategy favors accumulation on dips into the recent support zone around the 50-day SMA and prior consolidation low. Stalking is recommended until price shows tangible acceptance at these levels before executing a buy.

• ↑Q2 2026 net revenues of $17B (+10.2% YoY) fueled by Skyrizi and Renvoke.
• ↑Adjusted EPS of $3.65 beat guidance; full-year revenue guide raised to $67.6B.
• ↓Humira revenues set to decline over $4B in 2026 due to biosimilars.